AMLX
NASDAQAmylyx Pharmaceuticals Inc.
News · 26 weeks52-64%
2026-04-192026-10-11
Mix3390d
- Insider12(36%)
- SEC Filings11(33%)
- Earnings4(12%)
- Other3(9%)
- Offering2(6%)
- Leadership1(3%)
Latest news
25 items- INSIDERSEC Form 4 filed by Amylyx Pharmaceuticals Inc.4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)
- PRAmylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual MeetingLate-breaking oral presentation to feature Phase 3 topline data highlighting avexitide’s efficacy and safety Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced it will present two presentations at the upcoming ObesityWeek® 2026 Annual Meeting, taking place November 14-17, 2026, in Washington, D.C. The first late-breaking oral presentation will feature topline results from the Phase 3 LUCIDITY clinical trial of avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist, in participants with post-bariatric hypoglycemia (PBH) following Roux-en-Y gastric bypass (RYGB) surgery. This follows the Company’s announcemen
- SECSEC Form 144 filed by Amylyx Pharmaceuticals Inc.144 - Amylyx Pharmaceuticals, Inc. (0001658551) (Subject)
- PRAmylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic ForumAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced that management will present at the Stifel 2026 Virtual Cardiometabolic Forum. The fireside chat will take place on Wednesday, September 30th, 2026, at 9:30 a.m. ET. A live webcast of the presentation can be accessed under "Events and Presentations" in the Investor section of the Company’s website, https://investors.amylyx.com/events-presentations, and will be available for replay for 90 days following the events. About Amylyx Pharmaceuticals At Amylyx, our mission is to usher in a new era of treating diseases with high unmet needs. Where others see challenges, we see opportunities that we pursue wi
- INSIDERCo-Chief Executive Officer Klee Justin B. sold $980,263 worth of shares (30,464 units at $32.18), decreasing direct ownership by 0.84% to 3,613,056 units (SEC Form 4) (for tax liability)4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)
- INSIDERCo-Chief Executive Officer Cohen Joshua B sold $980,504 worth of shares (30,464 units at $32.19), decreasing direct ownership by 0.84% to 3,613,123 units (SEC Form 4) (tax withholding)4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)
- INSIDERChief Legal Officer Mazzariello Gina sold $309,506 worth of shares (9,536 units at $32.46), decreasing direct ownership by 5% to 190,838 units (SEC Form 4) to cover taxes4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)
- INSIDERChief Financial Officer Frates James M sold $349,821 worth of shares (10,810 units at $32.36), decreasing direct ownership by 4% to 233,625 units (SEC Form 4) to satisfy tax liability4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)
- INSIDERChief Medical Officer Bedrosian Camille L sold $324,868 worth of shares (10,028 units at $32.40), decreasing direct ownership by 3% to 278,064 units (SEC Form 4) to satisfy tax liability4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)
- SECSEC Form 144 filed by Amylyx Pharmaceuticals Inc.144 - Amylyx Pharmaceuticals, Inc. (0001658551) (Subject)
- SECSEC Form 144 filed by Amylyx Pharmaceuticals Inc.144 - Amylyx Pharmaceuticals, Inc. (0001658551) (Subject)
- PRTortugas Neuroscience Announces Appointment of Jim Frates to Board of DirectorsTortugas Neuroscience ("Tortugas"), a clinical-stage central nervous system (CNS)-focused biotech company developing medicines with clinically validated mechanisms of action in indications with both substantial patient populations and high unmet need, today announced the appointment of Jim Frates to its Board of Directors and as Chair of the Audit Committee. A highly experienced biopharmaceutical leader who has served as chief financial officer (CFO) for multiple public and private biotechnology companies, Frates currently serves as CFO of Amylyx Pharmaceuticals (NASDAQ:AMLX). "Jim’s wealth of experience in CNS drug development, coupled with his deep financial acumen, will be invaluable t
- SECSEC Form 8-K filed by Amylyx Pharmaceuticals Inc.8-K - Amylyx Pharmaceuticals, Inc. (0001658551) (Filer)
- PRAmylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare ConferenceAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced that management will present at the 24th Annual Morgan Stanley Global Healthcare Conference. The fireside chat will take place on Tuesday, September 15th, 2026, at 12:20 p.m. ET. A live webcast of the presentation can be accessed under "Events and Presentations" in the Investor section of the Company’s website, https://investors.amylyx.com/events-presentations, and will be available for replay for 90 days following the events. About Amylyx Pharmaceuticals At Amylyx, our mission is to usher in a new era of treating diseases with high unmet needs. Where others see challenges, we see opportunities that
- INSIDERDirector Firestone Karen exercised 50,000 shares at a strike of $3.40, increasing direct ownership by 75% to 116,900 units (SEC Form 4)4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)
- INSIDERChief Financial Officer Frates James M was granted 22,807 shares, increasing direct ownership by 10% to 244,435 units (SEC Form 4)4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)
- INSIDERCo-Chief Executive Officer Klee Justin B. was granted 60,039 shares, increasing direct ownership by 2% to 3,643,520 units (SEC Form 4)4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)
- INSIDERChief Legal Officer Mazzariello Gina was granted 21,284 shares, increasing direct ownership by 12% to 200,374 units (SEC Form 4)4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)
- INSIDERCo-Chief Executive Officer Cohen Joshua B was granted 60,039 shares, increasing direct ownership by 2% to 3,643,587 units (SEC Form 4)4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)
- INSIDERChief Medical Officer Bedrosian Camille L was granted 22,807 shares, increasing direct ownership by 9% to 288,092 units (SEC Form 4)4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)
- SECSEC Form 424B5 filed by Amylyx Pharmaceuticals Inc.424B5 - Amylyx Pharmaceuticals, Inc. (0001658551) (Filer)
- SECSEC Form 8-K filed by Amylyx Pharmaceuticals Inc.8-K - Amylyx Pharmaceuticals, Inc. (0001658551) (Filer)
- PRAmylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common StockAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced the pricing of an upsized underwritten public offering of 14,090,000 shares of its common stock at a public offering price of $35.50 per share. In addition, Amylyx has granted the underwriters a 30-day option to purchase up to an additional 2,113,500 shares of its common stock at the public offering price per share, less underwriting discounts and commissions. All of the shares of common stock are being offered by Amylyx. The gross proceeds to Amylyx from this offering are expected to be $500.2 million, before deducting underwriting discounts and commissions and offering expenses and excluding any exercis
- SECSEC Form 424B5 filed by Amylyx Pharmaceuticals Inc.424B5 - Amylyx Pharmaceuticals, Inc. (0001658551) (Filer)
- PRAmylyx Pharmaceuticals Announces $350.0 Million Proposed Public Offering of Common StockAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced that it has commenced an underwritten public offering of $350.0 million of shares of its common stock. In addition, Amylyx intends to grant the underwriters a 30-day option to purchase up to an additional $52.5 million of shares of its common stock at the public offering price per share, less underwriting discounts and commissions. All of the shares of common stock are being offered by Amylyx. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Amylyx intends to use t
AMLX FAQ
7 questionsWhat does Amylyx Pharmaceuticals Inc. do?
Amylyx Pharmaceuticals, Inc., a biopharmaceutical company, develops therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases in the United States and Canada. The company's product candidature includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and tauroursodeoxycholic acid for the treatment of ALS and other neurodegenerative diseases. It is also developing products for Wolfram syndrome and Alzheimer's diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.Where does AMLX stock trade?
Amylyx Pharmaceuticals Inc. (AMLX) is listed on NASDAQ.What sector and industry is AMLX in?
Amylyx Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Amylyx Pharmaceuticals Inc. go public?
Amylyx Pharmaceuticals Inc. (AMLX) completed its IPO in 2022.What are analysts saying about AMLX?
Amylyx Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from Stifel: Buy with a $2100.00 price target on 2026-03-03. Recent price targets range from $700.00 to $2100.00.What companies are similar to AMLX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare AMLX side-by-side with any of them on Quantisnow.How can I track AMLX on Quantisnow?
Quantisnow aggregates Amylyx Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AMLX to receive live email and push alerts on every new disclosure.